Evogene Ltd. Files September 2025 6-K Report
Ticker: EVGN · Form: 6-K · Filed: Sep 10, 2025 · CIK: 1574565
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
Related Tickers: EVGN
TL;DR
EVGN filed a 6-K for Sept 2025, standard foreign private issuer report.
AI Summary
Evogene Ltd. filed a Form 6-K on September 10, 2025, reporting for the month of September 2025. The filing is a report of a foreign private issuer and includes an exhibit incorporated by reference. Evogene Ltd. is an agriculture chemicals company based in Rehovot, Israel.
Why It Matters
This filing indicates ongoing reporting activity for Evogene Ltd., a foreign private issuer, which is important for investors tracking the company's regulatory compliance and disclosures.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain new material financial information or strategic changes.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- 001-36187 (company) — SEC File Number
- 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (company) — Principal executive offices address
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
What period does this report cover?
This report is for the month of September 2025.
What is the company's SEC file number?
The company's SEC file number is 001-36187.
Where is Evogene Ltd. located?
Evogene Ltd.'s principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Does Evogene Ltd. file annual reports under Form 20-F?
Yes, Evogene Ltd. indicates it files annual reports under Form 20-F.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2025-09-10 07:00:27
Filing Documents
- zk2533771.htm (6-K) — 8KB
- exhibit_99-1.htm (EX-99.1) — 49KB
- image00001.jpg (GRAPHIC) — 67KB
- image00002.jpg (GRAPHIC) — 80KB
- image00003.jpg (GRAPHIC) — 52KB
- img101_v1.jpg (GRAPHIC) — 159KB
- img102_v1.jpg (GRAPHIC) — 157KB
- img103_v1.jpg (GRAPHIC) — 122KB
- img104_v1.jpg (GRAPHIC) — 143KB
- img105_v1.jpg (GRAPHIC) — 116KB
- img106_v1.jpg (GRAPHIC) — 219KB
- img107_v1.jpg (GRAPHIC) — 166KB
- img108_v1.jpg (GRAPHIC) — 85KB
- img109_v1.jpg (GRAPHIC) — 95KB
- img110_v1.jpg (GRAPHIC) — 166KB
- img111_v1.jpg (GRAPHIC) — 107KB
- img112_v1.jpg (GRAPHIC) — 171KB
- img113_v1.jpg (GRAPHIC) — 124KB
- img114_v1.jpg (GRAPHIC) — 120KB
- img115_v1.jpg (GRAPHIC) — 67KB
- img116_v1.jpg (GRAPHIC) — 171KB
- img118_v1.jpg (GRAPHIC) — 213KB
- img119_v1.jpg (GRAPHIC) — 141KB
- img120_v1.jpg (GRAPHIC) — 130KB
- img121_v1.jpg (GRAPHIC) — 168KB
- img124_v1.jpg (GRAPHIC) — 67KB
- img125_v1.jpg (GRAPHIC) — 88KB
- img126_v1.jpg (GRAPHIC) — 106KB
- img127_v1.jpg (GRAPHIC) — 141KB
- img128_v1.jpg (GRAPHIC) — 124KB
- img129_v1.jpg (GRAPHIC) — 154KB
- 0001178913-25-003287.txt ( ) — 5178KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____ CONTENTS Attached hereto and incorporated by reference herein is the following exhibit: 99.1 Evogene Investor Presentation. Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 10, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer